Naramig (Naratriptan)

Naratriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, reducing migraine pain.

The appropriate dose of Naramig is determined by a qualified prescriber based on the individual patient's clinical condition, medical history, and response to therapy. Patients should follow the dosing instructions provided by their healthcare professional.

The safety of naratriptan in pregnancy and lactation has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks before prescribing Naramig to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Naramig (naratriptan) belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics. Compared with other triptans, naratriptan has a longer half‑life, offering extended migraine coverage, but individual response may vary.

Naramig tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect the tablets from moisture and direct sunlight to maintain their stability and potency.

Naramig is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the first sign of a migraine attack, unless otherwise directed by a healthcare professional.

Serious risks include chest pain or tightness, coronary artery spasm, severe hypertension, cardiac arrhythmias, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if any of these symptoms occur.

Naramig should be avoided in patients with uncontrolled hypertension, a history of ischemic heart disease or coronary vasospasm, severe hepatic impairment, or in those taking MAO inhibitors or other serotonergic agents without medical supervision.